Enlibrium Overview

  • Founded
  • 2015
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Enlibrium General Information

Description

Developer of novel drugs designed to treat a range of different cancers. The company's novel drugs are based on metformin that reduces cancer energy consumption and reestablishes energy balance.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • San Diego, CA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Enlibrium Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 28-Sep-2018 0000 Completed Out of Business
1. Early Stage VC (Series A) 03-Dec-2015 0000 0000 0000 Completed Startup
To view Enlibrium’s complete valuation and funding history, request access »

Enlibrium Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.0 00.0 00 00.0 000
To view Enlibrium’s complete cap table history, request access »

Enlibrium Patents

Enlibrium Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170210704-A1 Deutero-phenformin derivatives Abandoned 21-Jan-2016 0000000000